NIMG-52. ARTIFICIAL INTELLIGENCE-BASED VOLUMETRIC KINETICS FOR EVALUATING TREATMENT RESPONSE IN IDH-MUTANT GLIOMA TREATED WITH IMMUNOTHERAPY

Abstract BACKGROUND Interpretating radiographic findings of glioma patients receiving immunotherapy is challenging. Repeated imaging is often required for clinical decisions, potentially delaying next line of treatment. Here we assess a glioma segmentation AI model to evaluate treatment response in IDH-mutant glioma patients receiving nivolumab. METHODS Clinical magnetic resonance imaging (MRI)s from twenty-nine patients enrolled in a clinical trial (NCT03718767) were retrospectively analyzed. All patients had at least two sequential MRIs, including baseline study. T2, T1 (pre/post-contrast), and T2 FLAIR MRI sequences were pre-processed using publicly available AI-based whole-brain segmentation models. Lesion contours were derived from a validated 4-class brain tumor segmentation AI model, distinguishing healthy brain parenchyma, peri-lesional edema, non-contrast enhancing volume (NEV), and contrast-enhancing volume (CEV). Total lesion burden volume (TLBV=NEV + CEV + Edema) was also calculated. Growth rates between responders (R) and non-responders (NR), defined as progression-free survival ≥ or < 6months, respectively, were compared using a Wilcoxon Rank Sum Test. RESULTS The R group displayed significantly lower median rates of change for CEV (R -35% vs. NR +142% p = 4.31e-04) and TLBV (R +6% vs NR +43% p = 1.55e-03), compared to NR from baseline to post-cycle 1-2. Additionally, similar trends persisted at post-cycle 3-4 for CEV (R -41% vs. NR +367% p = 3.03e-03) and TLBV (R +12% vs. NR +40% p = 7.74e-03). Although NR showed a higher average baseline TLBV, there was no discernible correlation detected between baseline TLBV and the rate of change during treatment. CONCLUSIONS AI-based volumetric analysis offers an objective response assessment, showing promise in tracking disease progression in IDH-mutant glioma patients on nivolumab, potentially enabling earlier identification of progressive disease and allowing for timely treatment adjustments. A larger prospective study is warranted to refine volumetric pattern analysis for early clinical decisions in immunotherapy.